Mr. J. Roderick Matheson reports

MARVEL BIOSCIENCES ANNOUNCES GRANT OF DEFERRED SHARE UNITS

Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., have awarded 50,001 deferred share units (DSUs) to Marvel's three independent directors in lieu of cash payment for director fees.

The DSUs will all vest on May 19, 2027. Vested DSUs shall be settled upon the directors' separation from service from the company and expire 365 days after such directors' separation from service.

The deemed value for the DSUs is calculated using the VWAP (volume-weighted average price) of the corporation's common shares on the TSX Venture Exchange on May 19, 2026, being 15 cents, multiplied by the number of DSUs awarded.

About Marvel Biosciences Corp.

Marvel Biosciences is a Calgary-based preclinical-stage pharmaceutical development biotechnology company. The company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug, istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's disease. The company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett syndrome and fragile X syndrome, to expand its therapeutic reach.

We seek Safe Harbor.